By demonstrating the clinical relevance of HER2-low as an independent therapeutic subgroup, T-DXd is now a new paradigm-disrupting ADC that can address both high and low HER2-expressing disease in a way that revolutionizes our approach to rating and treating breast cancer [53]. This evidence concerns the gene ERBB2 and breast cancer.